Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 145-149
10.1182/blood-2022-158030